Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
119 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2014', provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Ankylosing Spondylitis (Bekhterev's Disease) Overview 9 Therapeutics Development 10 Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview 10 Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis 11 Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies 12 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies 18 Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development 19 Boehringer Ingelheim GmbH 19 Piramal Enterprises Limited 20 Celltrion, Inc. 21 Novartis AG 22 Biocon Limited 23 Pfizer Inc. 24 Sandoz Inc. 25 Celgene Corporation 26 Lupin Limited 27 Panacea Biotec Limited 28 Avesthagen Limited 29 Covagen AG 30 Biosidus S.A. 31 Inbiopro Solutions Pvt. Ltd. 32 Innovent Biologics, Inc. 33 Epirus Biopharmaceuticals, Inc. 34 AlphaMab Co., Ltd 35 Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 40 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 infliximab biosimilar - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 apremilast - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 secukinumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 etanercept biosimilar - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 adalimumab biosimilar - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 tofacitinib - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BI-655066 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 infliximab biosimilar - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 COVA-322 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 adalimumab biosimilar - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 etanercept biosimilar - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 P-979 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 etanercept biosimilar - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 adalimumab biosimilar - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 etanercept biosimilar - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 IBPM-005IX - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 IBPM-004AM - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 etanercept biosimilar - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 etanercept biosimilar - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 adalimumab biosimilar - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 adalimumab biosimilar - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 adalimumab biosimilar - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 INV-17 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 etanercept biosimilar - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 IBI-303 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ND-007 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 adalimumab biosimilar - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 etanercept biosimilar - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates 82 Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects 106 Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products 107 Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones 108 Featured News & Press Releases 108 Jul 09, 2014: Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis 108 Apr 10, 2014: Horizon Pharma Announces the U.S. Patent and Trademark Office Issued an Additional Notice of Allowance With Claims Covering RAYOS (Prednisone) Delayed-Release Tablets 109 Oct 18, 2013: Cimzia Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis 110 Sep 11, 2013: Hospira's Inflectra the first biosimilar monoclonal antibody to be approved in Europe 111 Sep 05, 2013: Horizon Pharma Announces Sanofi Compiegne as Additional Manufacturing Site for DUEXIS 113 Aug 22, 2013: Horizon Pharma Announces Settlement of DUEXIS Patent Litigation With Par Pharmaceutical 113 Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 114 Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 115 May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 117 Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare 117 Appendix 118 Methodology 118 Coverage 118 Secondary Research 118 Primary Research 118 Expert Panel Validation 118 Contact Us 119 Disclaimer 119
List of Tables Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2014 10 Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Comparative Analysis by Unknown Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 19 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Piramal Enterprises Limited, H2 2014 20 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H2 2014 21 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2014 22 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H2 2014 23 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H2 2014 24 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz Inc., H2 2014 25 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H2 2014 26 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H2 2014 27 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H2 2014 28 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H2 2014 29 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Covagen AG., H2 2014 30 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biosidus S.A., H2 2014 31 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 32 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H2 2014 33 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 34 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AlphaMab Co., Ltd, H2 2014 35 Assessment by Monotherapy Products, H2 2014 36 Number of Products by Stage and Target, H2 2014 39 Number of Products by Stage and Mechanism of Action, H2 2014 42 Number of Products by Stage and Route of Administration, H2 2014 44 Number of Products by Stage and Molecule Type, H2 2014 46 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H2 2014 82 Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2014 106 Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2014 107
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
